CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
personal-finance
CSL: Why I’m still holding
markets
Market Minute: Reporting Season, Part 2
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.90 | 2.50 | -0.03% |
| CAC 40 | 7,712.05 | 37.27 | 0.49% |
| DAX 40 | 23,761.84 | 164.86 | 0.70% |
| Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
| FTSE 100 | 9,221.04 | 12.83 | 0.14% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,700.39 | 7.30 | -0.03% |
| Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
| NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
| S&P 500 | 6,481.50 | 20.58 | -0.32% |
| S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |